News

b

b

Current News in Drug Discovery

RSS Nature Reviews Drug Discovery
  • Accelerating clinical trials in the EU (ACT EU): transforming the EU clinical trials landscape May 23, 2024
    Nature Reviews Drug Discovery, Published online: 23 May 2024; doi:10.1038/d41573-024-00085-5Accelerating Clinical Trials in the EU (ACT EU) is an initiative developed by the European Commission, Heads of Medicines Agencies and the European Medicines Agency to transform the clinical trials landscape in the European Union. It aims to foster regulatory, technological and process innovation to support […]
    Giacomo Capone
  • Navigating the complexities of drug development for inflammatory bowel disease May 22, 2024
    Nature Reviews Drug Discovery, Published online: 22 May 2024; doi:10.1038/s41573-024-00953-0Drug discovery and development for inflammatory bowel disease (IBD) is hampered by various challenges including the insufficient mechanistic understanding of IBD immunopathology, disease heterogeneity, inadequate preclinical models and clinical trial inefficiencies. This Perspective assesses these limitations and presents strategies to overcome them, including the integration of […]
    Sailish Honap
  • The state of the art in secondary pharmacology and its impact on the safety of new medicines May 21, 2024
    Nature Reviews Drug Discovery, Published online: 21 May 2024; doi:10.1038/s41573-024-00942-3Secondary pharmacology screening of investigational small-molecule drugs for potentially adverse off-target activities is now standard practice in pharmaceutical research and development. This article uses a survey across 18 companies as the basis for discussing strategies for implementing secondary pharmacology screening programmes, approaches for interpreting off-target activities […]
    Richard J. Brennan
  • RNA-rewriting candidate moves into the clinic May 20, 2024
    Nature Reviews Drug Discovery, Published online: 20 May 2024; doi:10.1038/d41573-024-00086-4‘Pre-mRNA trans-splicing’ drugs could offer an alternative to gene replacement therapies for genetic diseases — starting with Stargardt disease.
    Asher Mullard
  • Tackling the challenges of new approach methods for predicting drug effects from model systems May 15, 2024
    Nature Reviews Drug Discovery, Published online: 15 May 2024; doi:10.1038/d41573-024-00081-9The passage of the FDA Modernization Act 2.0 in 2022 has provided additional impetus to develop new approach methods for predicting the effects of drug candidates in humans from models such as microphysiological systems based on human-derived induced pluripotent stem cells. Here, we highlight progress in […]
    Paul D. Pang
  • Combating antimicrobial resistance in malaria, HIV and tuberculosis May 15, 2024
    Nature Reviews Drug Discovery, Published online: 15 May 2024; doi:10.1038/s41573-024-00933-4The rise of drug resistance presents a significant challenge in the treatment of infectious diseases. This Review summarizes the status and mechanisms of drug resistance in malaria, human immunodeficiency virus (HIV) infection and tuberculosis, and explores strategies to address resistance that could be incorporated into drug […]
    Maëlle Duffey
  • Publisher Correction: Roflumilast May 15, 2024
    Nature Reviews Drug Discovery, Published online: 15 May 2024; doi:10.1038/s41573-024-00960-1Publisher Correction: Roflumilast
    Leonardo M. Fabbri
  • CXCR4 chemokine antagonist scores a first FDA approval for WHIM syndrome May 13, 2024
    Nature Reviews Drug Discovery, Published online: 13 May 2024; doi:10.1038/d41573-024-00083-7CXCR4 chemokine antagonist scores a first FDA approval for WHIM syndrome
    Asher Mullard

Vitreon America™ Launches Botanicopeia™ Database and Federal Government Services at NIH Festival+

 BETHESDA, MD, September 17, 2016 − Vitreon America, Inc. participated this week in the National Institute of Health (NIH) Intramural Research Program’s 30th Annual NIH Research Festival which was held September 15-16, 2016 at the NIH Bethesda, Maryland campus.

The Festival included plenary sessions, symposia, exhibits, poster sessions and tours designed to encourage sharing and learning about the exciting research taking place on NIH campus.

Vitreon America was selected by the Technical Sales Association (TSA) which sponsors the Research Festival Exhibit, to launch its state-of-the-art Phytochemical and Ethnobotanical database subscription services, Botanicopeia.

Attending on behalf of Vitreon America
were Michael Megginson, VP of Business Development (left) and Jorgen Sandberg,
CEO (right).

Vitreon America was pleased to see the interest from the NIH Institutions to utilize the Botanicopeia database subscriptions with many NIH researchers expressing interest in considering the Vitreon America Botanical Research Analytic services as well to optimize the Botanicopeia database.

Based on the NIH researchers feedback, Vitreon America has established a Botanicopeia database subscription service agreement and subscription service with botanical research analytic services through Marshall Communications Corporation, www.marshallcomm.com.

Vitreon America services are available through Marshall Communications Corporation (VOSB) on NIH’s Information Technology Acquisition and Assessment Center’s (NITAAC)- Government-wide Acquisition Contract (GWAC) vehicle. [Prime Contract Holder #HHSN316201500063W]

Vitreon America was established with the goal of commercializing their Botanicopeia database and botanical research analytic services for development of botanicals and phytochemicals in the creation of new medicinal products by Vitreon America Clients.

To find out more about our Services please contact us for assistance at 1-888-214-2584 or at info@vitreonamerica.com

About Vitreon America™

Vitreon AmericaTM was formed with the goal of disseminating their BotanicopeiaTM database to encourage the increased use of botanicals and phytochemicals in the creation of new medicines.

Contact Vitreon America, Inc.

Vitreon America Botanical Research Center @ Hopkins Johns Hopkins University

MCC 9601 Medical Center Drive, Suite 221
Rockville, Maryland 20850

+1-888-214-2584

j.shaver@advasur.com